NSAIDs reduce mortality in colorectal cancer
November 11th 2009Prediagnosis regular nonsteroidal anti-inflammatory drug (NSAID) use and prolonged duration of NSAID use were independently associated with decreased overall mortality and colorectal cancer (CRC) mortality in women with a first primary invasive CRC, according to a large cohort study.
Thiopurines increase lymphoproliferative disorder risk in IBD patients
November 1st 2009Patients with inflammatory bowel disease receiving thiopurines are at increased risk of developing lymphoproliferative disorder, according to a French prospective observational cohort study, which was published online in The Lancet.
Bloodstream infections and contaminated prefilled syringes: issues of medication safety
November 1st 2009An investigation into a multistate outbreak of Serratia marcescens bloodstream infections (BSIs) published in the Archives of Internal Medicine found an association between the BSIs and contamination of prefilled syringes.
Two antimalaria drugs are tolerated regimens in regions with resistance
November 1st 2009In a review published in The Cochrane Library, researchers determined that atovaquone-proguanil and doxycycline were well tolerated by most travelers and are less likely than mefloquine to cause adverse neuropsychiatric outcomes.
Study results show risk factors for ulcer development among NSAID users
October 29th 2009Horizon Therapeutics Inc., a privately held biopharmaceutical company, recently presented an analysis from 2 pivotal phase 3 trials (REDUCE-1 and REDUCE-2) evaluating its lead investigational compound HZT-501, a combination of ibuprofen with high-dose famotidine, PRNewswire reports.
Three diet drugs in final stages of research and development
October 29th 2009Three prescription diet drugs are in the final stages of development. According to USA Today, the drugs' manufacturers still have to submit their new drug applications to FDA and go through a rigorous review and approval process.
Comparative effectiveness research could threaten personalized medicine, NIH director warns
October 29th 2009The federal government?s push to control health costs through comparative effectiveness research could threaten strides in personalized medicine, in which medicines are tailored to an individual?s genetic makeup, said the National Institutes of Health chief at a recent forum sponsored by the American Association for the Advancement of Science.